Defective BARD1 does not bind BRCA1

Stable Identifier
R-HSA-9699163
Type
Reaction [transition]
Species
Homo sapiens
Compartment
nucleoplasm
ReviewStatus
5/5
Locations in the PathwayBrowser
Expand all
General
SVG | 
PNG
Low
Medium
High
 | PPTX  | SBGN
Defective BARD1 does not bind BRCA1
Click the image above or here to open this reaction in the Pathway Browser
The layout of this reaction may differ from that in the pathway view due to the constraints in pathway layout
The N-terminal RING domain and C-terminal BRCT repeats of BARD1 contribute to its binding to BRCA1 (Simons et al. 2006). While not frequently reported in cancer, missense mutations in these two regions of BARD1 affect BARD1 function in homology directed repair (HDR) by impairing its interaction with BRCA1 and may potentially contribute to hereditary breast and ovarian cancer (Lee et al. 2015).

The following BARD1 missense mutants have been reported in hereditary breast and ovarian cancer and shown to be impaired in their interaction with BRCA1 and in HDR:
BARD1 C53W (Lee et al. 2015; the C53W substitution produces an insoluble BARD1 protein)
BARD1 C71Y (Morris et al. 2002; Lee et al. 2015; the C71Y substitution produces an insoluble BARD1 protein)
BARD1 G623E (Lee et al. 2015).

The following BARD1 mutants impaired in their ability to bind to BRCA1 have been clinically reported but not in cancer samples and are annotated as candidates:

BARD1 W34R (Lee et al. 2015 - studied as a synthetic mutant, but is in ClinGen Allele Registry, Pawliczek et al. 2018)
BARD1 L44R (Morris et al. 2002, Lee et al. 2015 - studied as a synthetic mutant, but is in ClinGen Allele Registry, Pawliczek et al. 2018)
BARD1 C50G (Xia et al. 2003)
BARD1 C83G (Xia et al. 2003)

The following BARD1 mutants reported in cancer and predicted to be pathogenic have not been tested for their ability to bind to BRCA1 but share sequence similarity with functionally characterized BARD1 mutants:
BARD1 H68Y (similar to functionally characterized synthetic mutant BARD1 H68A, described in Xia et al. 2003)
BARD1 G632W (similar to functionally characterized cancer mutant BARD1 G623E, described in Lee et al. 2015).
Literature References
PubMed ID Title Journal Year
30311374 ClinGen Allele Registry links information about genetic variants

Clinical Genome (ClinGen) Resource, -, Wright, MW, Bizon, C, Zhen, J, Milosavljevic, A, Landrum, M, McGarvey, P, Freimuth, RR, Powell, B, Ashmore, LR, Shah, N, Jackson, AR, Pawliczek, P, Babb, L, Patel, RY, Nelson, T, Plon, SE, Dwight, S, Paithankar, S, Strande, N

Hum. Mutat. 2018
26350354 Functional Analysis of BARD1 Missense Variants in Homology-Directed Repair of DNA Double Strand Breaks

Parvinsmith, MR, Ceravolo, A, Banerjee, T, Gillespie, J, Fields, S, Parvin, JD, Toland, AE, Lee, C, Starita, LM

Hum. Mutat. 2015
12431996 Enhancement of BRCA1 E3 ubiquitin ligase activity through direct interaction with the BARD1 protein

Pao, GM, Xia, Y, Verma, IM, Chen, HW, Hunter, T

J. Biol. Chem. 2003
16489000 BRCA1 DNA-binding activity is stimulated by BARD1

Parvin, JD, Horwitz, AA, Glover, JN, Griffin, K, Williams, RS, Starita, LM, Simons, AM

Cancer Res. 2006
Participants
Input
Participates
as an event of
Normal reaction
BRCA1 forms a heterodimer with BARD1 (Homo sapiens)
Functional status

Loss of function and partial loss of function of BARD1 mutants (BRCA1 binding) [nucleoplasm]

Normal Entity
Disease Entity
Status
Disease
Name Identifier Synonyms
cancer DOID:162 malignant tumor, malignant neoplasm, primary cancer
Authored
Orlic-Milacic, M  (2020-09-30)
Reviewed
Baer, RJ  (2020-11-04)
Created
Orlic-Milacic, M  (2020-09-11)
Cite Us!